The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis
Abstract
Objective: To evaluate the extent to which treatment effect on brain atrophy is able to mediate, at the trial level, the treatment effect on disability progression in relapsing–remitting multiple sclerosis (RRMS). Methods: We collected all published randomized clinical trials in RRMS lasting at least 2 years and including as endpoints disability progression (defined as 6 or 3 months confirmed 1‐point increase on the Expanded Disability Status Scale), active magnetic resonance imaging (MRI) lesions (defined as new/enlarging T2 lesions), and brain atrophy (defined as change in brain volume between month 24 and month 6–12). Treatment effects were expressed as relative reductions. A linear regression, weighted for trial size and duration, was used to assess the relationship between the treatment effects on MRI markers and on disability progression. Results: Thirteen trials including >13,500 RRMS patients were included in the meta‐analysis. Treatment effects on disability progression were correlated with treatment effects both on brain atrophy ( R 2 = 0.48, p = 0.001) and on active MRI lesions ( R 2 = 0.61, p < 0.001). When the effects on both MRI endpoints were included in a multivariate model, the correlation was higher ( R 2 = 0.75, p < 0.001), and both variables were retained as independently related to the treatment effect on disability progression. Interpretation: In RRMS, the treatment effect on brain atrophy is correlated with the effect on disability progression over 2 years. This effect is independent of the effect of active MRI lesions on disability; the 2 MRI measures predict the treatment effect on disability more closely when used in combination. ANN NEUROL 2014;75:43–49
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
Polman, C. H., O'Connor, P. W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D. H., Phillips, J. T., Lublin, F. D., Giovannoni, G., Wajgt, A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044397 · Cited by 3,386
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Kappos, L., Radue, E.-W., O'Connor, P., Polman, C., Hohlfeld, R., Calabresi, P., Selmaj, K., Agoropoulou, C., Leyk, M., Zhang-Auberson, L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909494 · Cited by 2,644
Surrogate endpoints in clinical trials: Definition and operational criteria
Prentice, R. L. (1989) · Statistics in Medicine · doi:10.1002/sim.4780080407 · Cited by 2,057
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
Gold, R., Kappos, L., Arnold, D. L., Bar-Or, A., Giovannoni, G., Selmaj, K., Tornatore, C., Sweetser, M. T., Yang, M., Sheikh, S. I., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114287 · Cited by 1,733
Self-citationPlacebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
Fox, R. J., Miller, D. H., Phillips, J. T., Hutchinson, M., Havrdova, E., Kita, M., Yang, M., Raghupathi, K., Novas, M., Sweetser, M. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206328 · Cited by 1,355
Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis
Rudick, R. A., Stuart, W. H., Calabresi, P. A., Confavreux, C., Galetta, S. L., Radue, E.-W., Lublin, F. D., Weinstock-Guttman, B., Wynn, D. R., Lynn, F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044396 · Cited by 1,344
Cohen, J. A., Coles, A. J., Arnold, D. L., Confavreux, C., Fox, E. J., Hartung, H.-P., Havrdova, E., Selmaj, K. W., Weiner, H. L., Fisher, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61769-3 · Cited by 1,205
Self-citationColes, A. J., Twyman, C. L., Arnold, D. L., Cohen, J. A., Confavreux, C., Fox, E. J., Hartung, H.-P., Havrdova, E., Selmaj, K. W., Weiner, H. L., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61768-1 · Cited by 1,198
Self-citationA Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
Giovannoni, G., Comi, G., Cook, S., Rammohan, K., Rieckmann, P., Sørensen, P. S., Vermersch, P., Chang, P., Hamlett, A., Musch, B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0902533 · Cited by 1,023
Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
O'Connor, P., Wolinsky, J. S., Confavreux, C., Comi, G., Kappos, L., Olsson, T. P., Benzerdjeb, H., Truffinet, P., Wang, L., Miller, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014656 · Cited by 990
Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS
Rudick, R. A., Fisher, E., Lee, J.-C., Simon, J., Jacobs, L., & the Multiple Sclerosis Collaborative Research Group (1999) · Neurology · doi:10.1212/wnl.53.8.1698 · Cited by 736
Normalized Accurate Measurement of Longitudinal Brain Change
Smith, S. M., De Stefano, N., Jenkinson, M., & Matthews, P. M. (2001) · Journal of Computer Assisted Tomography · doi:10.1097/00004728-200105000-00022 · Cited by 488
Self-citationMikol, D. D., Barkhof, F., Chang, P., Coyle, P. K., Jeffery, D. R., Schwid, S. R., Stubinski, B., & Uitdehaag, B. M. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70200-x · Cited by 486
O'Connor, P., Filippi, M., Arnason, B., Comi, G., Cook, S., Goodin, D., Hartung, H.-P., Jeffery, D., Kappos, L., Boateng, F., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70226-1 · Cited by 405
Imaging outcomes for neuroprotection and repair in multiple sclerosis trials
Barkhof, F., Calabresi, P. A., Miller, D. H., & Reingold, S. C. (2009) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.41 · Cited by 378
Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes
De Stefano, N., Giorgio, A., Battaglini, M., Rovaris, M., Sormani, M. P., Barkhof, F., Korteweg, T., Enzinger, C., Fazekas, F., Calabrese, M., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e24136 · Cited by 321
Self-citationMRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials
Sormani, M. P., & Bruzzi, P. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70103-0 · Cited by 278
Self-citationMechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis
Zivadinov, R., Reder, A. T., Filippi, M., Minagar, A., Stüve, O., Lassmann, H., Racke, M. K., Dwyer, M. G., Frohman, E. M., & Khan, O. (2008) · Neurology · doi:10.1212/01.wnl.0000316810.01120.05 · Cited by 260
Amato, M. P., Portaccio, E., Goretti, B., Zipoli, V., Battaglini, M., Bartolozzi, M. L., Stromillo, M. L., Guidi, L., Siracusa, G., Sorbi, S., et al. (2007) · Archives of Neurology · doi:10.1001/archneur.64.8.1157 · Cited by 230
Self-citationSormani, M. P., Bonzano, L., Roccatagliata, L., Cutter, G. R., Mancardi, G. L., & Bruzzi, P. (2009) · Annals of Neurology · doi:10.1002/ana.21606 · Cited by 223
Self-citationDehydration confounds the assessment of brain atrophy
Duning, T., Kloska, S., Steinsträter, O., Kugel, H., Heindel, W., & Knecht, S. (2005) · Neurology · doi:10.1212/01.wnl.0000150542.16969.cc · Cited by 190 · cited 1×
“MRI-derived measures of global brain atrophy lack pathological specificity, as they may be related to changes in myelin, axon, or glial content, as well as physiological fluctuations due to factors such as changes in water content.(26) However, despite uncertainties regarding histopathological specificity, a substanti…”
BackgroundBrain atrophy and lesion load in a large population of patients with multiple sclerosis
Tedeschi, G., Lavorgna, L., Russo, P., Prinster, A., Dinacci, D., Savettieri, G., Quattrone, A., Livrea, P., Messina, C., Reggio, A., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000168837.87351.1f · Cited by 159
Surrogate endpoints for EDSS worsening in multiple sclerosis
Sormani, M. P., Bonzano, L., Roccatagliata, L., Mancardi, G., Uccelli, A., & Bruzzi, P. (2010) · Neurology · doi:10.1212/wnl.0b013e3181ea15aa · Cited by 116
Self-citationMRI metrics as surrogate markers for clinical relapse rate in relapsing-remitting MS patients
Sormani, M. P., Bruzzi, P., Comı, G., & Filippi, M. (2002) · Neurology · doi:10.1212/wnl.58.3.417 · Cited by 65
Self-citationMagnetic resonance active lesions as individual-level surrogate for relapses in multiple sclerosis
Sormani, M. P., Stubinski, B., Cornelisse, P., Rocak, S., Li, D., & Stefano, N. D. (2010) · Multiple Sclerosis Journal · doi:10.1177/1352458510391837 · Cited by 63
Self-citationSormani, M. P., Miller, D. H., Comı, G., Barkhof, F., Rovaris, M., Bruzzi, P., & Filippi, M. (2001) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.70.4.494 · Cited by 63
Self-citationMRI metrics as surrogate endpoints for EDSS progression in SPMS patients treated with IFN β-1b
Sormani, M. P., Bruzzi, P., Beckmann, K., Wagner, K., Miller, D., Kappos, L., & Filippi, M. (2003) · Neurology · doi:10.1212/01.wnl.0000063312.15758.b3 · Cited by 56
Self-citation
Cited by
Reich, D. S., Lucchinetti, C. F., & Calabresi, P. A. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1401483 · Cited by 2,491
Filippi, M., Bar-Or, A., Piehl, F., Preziosa, P., Solari, A., Vukusic, S., & Rocca, M. A. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0041-4 · Cited by 1,562
on behalf of the MAGNIMS study group (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.157 · Cited by 473
Brain health: time matters in multiple sclerosis
Giovannoni, G., Butzkueven, H., Dhib-Jalbut, S., Hobart, J., Kobelt, G., Pepper, G., Sormani, M. P., Thalheim, C., Traboulsee, A., & Vollmer, T. (2016) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2016.07.003 · Cited by 458
Self-citationOptical coherence tomography reflects brain atrophy in multiple sclerosis: A four‐year study
Saidha, S., Al‐Louzi, O., Ratchford, J. N., Bhargava, P., Oh, J., Newsome, S. D., Prince, J. L., Pham, D., Roy, S., van Zijl, P., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24487 · Cited by 391
Metadata
- Authors
- Sormani, M. P., Arnold, D. L., & De Stefano, N.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2014-01
- Volume
- 75
- Issue
- 1
- Pages
- 43-49
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W1567125068
- Cited by
- 297
- References
- 27
- FWCI
- 19.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.